Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ... Cancer cell 7 (4), 387-397, 2005 | 3843 | 2005 |
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, ... Nature 462 (7269), 108-112, 2009 | 3146 | 2009 |
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ... New England Journal of Medicine 358 (18), 1909-1918, 2008 | 2098 | 2008 |
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ... New England Journal of Medicine 350 (16), 1605-1616, 2004 | 1249 | 2004 |
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML … S Fröhling, RF Schlenk, J Breitruck, A Benner, S Kreitmeier, K Tobis, ... Blood, The Journal of the American Society of Hematology 100 (13), 4372-4380, 2002 | 1118 | 2002 |
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene … K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ... Blood 106 (12), 3740-3746, 2005 | 1116 | 2005 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ... Nature 455 (7215), 975-978, 2008 | 1017 | 2008 |
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 706 | 2012 |
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations S Fröhling, RF Schlenk, I Stolze, J Bihlmayr, A Benner, S Kreitmeier, ... Journal of Clinical Oncology 22 (4), 624-633, 2004 | 632 | 2004 |
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells C Scholl, S Fröhling, IF Dunn, AC Schinzel, DA Barbie, SY Kim, SJ Silver, ... Cell 137 (5), 821-834, 2009 | 619 | 2009 |
Genetics of myeloid malignancies: pathogenetic and clinical implications S Fröhling, C Scholl, DG Gilliland, RL Levine Journal of clinical oncology 23 (26), 6285-6295, 2005 | 513 | 2005 |
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia MG Kharas, CJ Lengner, F Al-Shahrour, L Bullinger, B Ball, S Zaidi, ... Nature medicine 16 (8), 903-908, 2010 | 419 | 2010 |
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal … K Döhner, K Tobis, R Ulrich, S Fröhling, A Benner, RF Schlenk, ... Journal of Clinical Oncology 20 (15), 3254-3261, 2002 | 406 | 2002 |
Caring for patients with cancer in the COVID-19 era J van de Haar, LR Hoes, CE Coles, K Seamon, S Fröhling, D Jäger, ... Nature medicine 26 (5), 665-671, 2020 | 383 | 2020 |
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B S Fröhling, RF Schlenk, S Kayser, M Morhardt, A Benner, K Döhner, ... Blood 108 (10), 3280-3288, 2006 | 374 | 2006 |
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation S Raffel, M Falcone, N Kneisel, J Hansson, W Wang, C Lutz, L Bullinger, ... Nature 551 (7680), 384-388, 2017 | 325 | 2017 |
Sarcoma classification by DNA methylation profiling C Koelsche, D Schrimpf, D Stichel, M Sill, F Sahm, DE Reuss, M Blattner, ... Nature communications 12 (1), 498, 2021 | 317 | 2021 |
Chromosomal abnormalities in cancer S Fröhling, H Döhner New England Journal of Medicine 359 (7), 722-734, 2008 | 314 | 2008 |
Superior skin cancer classification by the combination of human and artificial intelligence A Hekler, JS Utikal, AH Enk, A Hauschild, M Weichenthal, RC Maron, ... European Journal of Cancer 120, 114-121, 2019 | 313 | 2019 |
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias SM Sykes, SW Lane, L Bullinger, D Kalaitzidis, R Yusuf, B Saez, F Ferraro, ... Cell 146 (5), 697-708, 2011 | 299 | 2011 |